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Background: The peptide apelin is localised in the vascular endothelium and highly expressed
in pulmonary tissue. The aim of this study was to investigate whether apelin could be a poten-
tial lung-derived plasma marker for pulmonary hypertension, and study the effect of apelin in
pulmonary arteries.
Methods: Apelin protein levels were measured in the lung, right ventricle, and plasma from
normoxic and chronic hypoxic rats with pulmonary hypertension. Isolated intrapulmonary
arteries were mounted in microvascular myographs and the effect of apelin investigated.
Finally, the distribution of apelin receptors in pulmonary tissue was visualised by immunohis-
tochemistry.
Results: Total pulmonary apelin content was not changed by hypoxia. Right ventricular apelin
concentrations and content were lower than in the lung, but increased substantially in hypoxia
in correlation with right ventricular pressure. Plasma apelin did not reflect pulmonary or right
ventricular apelin levels. In pulmonary arteries from normoxic rats, apelin inhibited vasocon-
striction to endothelin-1 and angiotensin-II. However, in arteries from hypoxic rats, apelin
failed to inhibit contraction to angiotensin-II and endothelin-1. No difference in immunoreac-
tion for apelin receptors was found in lung sections and arteries from normoxic versus chronic
hypoxic rats.
Conclusions: Apelin changes in the right ventricle seem more specific for pulmonary hyperten-
sion than do changes in pulmonary tissue, which does not speak in favour of apelin as a lung-
derived marker for this disease. During normoxic conditions, apelin has a modulating effect on
vasoconstriction which is lost in chronic hypoxia. This may reflect alterations in the signal
transduction downstream of the apelin receptor.
ª 2009 Elsevier Ltd. All rights reserved.42 17 91; fax: þ45 86 12 88 04.
.U. Andersen).
9 Elsevier Ltd. All rights reserved.
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Pulmonary hypertension is a severe disease with a median
survival of 2.8 years in the idiopathic form, if left
untreated.1 The late occurrence and non-specific character
of symptoms and clinical signs can delay diagnosis, which is
unfortunate because survival depends on disease stage at
the onset of treatment.2 Plasma biomarkers to help in the
diagnosis of pulmonary hypertension are desirable, and
various substances involved in the pathophysiology of
pulmonary hypertension have been proposed, e.g. endo-
thelin-1, serotonin, and nitric oxide (NO). However,
measurements of endothelin-1 are complicated by intra-
personal variability,3 a short half life in plasma and
pulmonary clearance.4 A few studies on plasma concen-
trations of serotonin have reported conflicting results of
elevated5 and normal6 concentrations in patients with
severe pulmonary hypertension. NO is difficult to measure
in the blood, and the second messenger cGMP is also
regulated by the natriuretic peptides.4 Uric acid levels are
higher in patients with pulmonary hypertension,7 but are
influenced by e.g. diet and kidney function. Consequently,
these substances are not yet established as markers for
pulmonary hypertension. Currently, the best validated
marker is brain natriuretic peptide (BNP), which is secreted
in response to ventricular overload.8 However, since the
origin of BNP is the heart, it is unlikely that BNP reflect
early stages of pulmonary hypertension, when right
ventricular strain has not yet occurred. Furthermore, BNP
may also be elevated in case of left ventricular
dysfunction.9
Recently, a newly discovered peptide, apelin, was
proposed as a marker of heart failure and pulmonary
hypertension.10 Apelin exists in lengths of e.g. 12, 13 and 36
aminoacids and is present in vascular endothelial cells, and
the expression is particularly high in pulmonary tissue.11
The peptide has a potent positive inotropic effect12 and in
systemic vascular tissue, apelin exerts vasodilatation and
inhibits angiotensin-II mediated vasoconstriction through
NO-dependent mechanisms.13,14 These effects seem to be
more pronounced for apelin peptides of 12 and 13 amino-
acids.15 Furthermore, the effects of the apelin system are
altered in cardiovascular disease.16,17 We hypothesised that
apelin could be a lung-derived plasma marker for pulmo-
nary hypertension and that it may have vasodilatory effects
in pulmonary vessels.
In accordance, the present study addressed how apelin
concentrations in the lung are affected by hypoxia-induced
pulmonary hypertension in rats, and whether pulmonary
apelin content is reflected in plasma. Furthermore, apelin
was measured in the right ventricle which is also affected in
chronic hypoxic rats. Finally, we investigated the effect of
apelin and the apelin receptor distribution in pulmonary
arteries from normoxic and chronic hypoxic rats.
Methods
Animals
9 Weeks old male Wistar rats were kept for 2 weeks in
normoxia or hypobaric hypoxia (550 mBar corresponding to10% of O2) to induce pulmonary hypertension. To evaluate
whether apelin levels correlated to pressure load rather
than hypoxia alone, a group of rats with intermediate right
ventricular pressures were created by treating 8 hypoxic
rats with the specific pulmonary vasodilator sildenafil,
25 mg/kg/day (Pfizer, Kent, UK), in the drinking water.18
The animals were kept on a 12:12-h lightedark cycle with
free access to water and chow and renewal of the cages
twice a week.
All experiments were performed with approval from the
Danish Institutional Animal Care and Use Committee.
Measurements of right ventricular systolic pressure
and collection of tissue
Rats used for measurements of apelin levels were anaes-
thetized by inhalation of isoflurane (4.5%, oxygen flow 2 l/
min, FORENE) (Abbott Scandinavia AB, Sweden) followed
by injection of dormicum (midazolam 5 mg/ml) (F. Hoff-
mann-La Roche AG, Basel, Switzerland) and hypnorm
(fentanyl citrate 0.315 mg/ml, fluanisone 10 mg/ml)
(VetaPharma Ltd, Leeds, UK) 1.8 mg/kg. Right ventricular
systolic pressures were measured by insertion through the
right jugular vein of a Millar catheter (model SPR-407 2F,
Micro-Tip Catheter) (Millar Instruments Inc, Houston, TX,
USA) connected to a QUAD Bridge, Powerlab 4/20 (AD
Instruments, UK) and Chart 5.5 software (AD Instruments,
UK). Rats were killed by exsanguination and lungs and heart
were removed en bloc and kept in cold physiological salt
solution (PSS) (NaCl 119 mM, KCl 4.7 mM, MgSO4 (7H2O)
1.17 mM, NaHCO3 25 mM, KH2PO4 1.18 mM, EDTA 0.026 mM,
glucose 5.5 mM). Wet weight of lungs, heart, right and left
heart ventricle plus septum was measured and the organs
were snap frozen in liquid nitrogen. Arterial blood was
collected in tubes containing EDTA (1 mg/ml sample) and
aprotinin (0.6 TIU/ml) (SigmaeAldrich, St. Louis, U.S.A.)
and centrifuged at 1600 g at 4 C for 15 min.
Apelin measurements
Lung and right ventricular tissues were squashed in liquid
nitrogen, homogenised in lysis buffer (5 ml/g of tissue) with
protease inhibitor cocktail for mammalian cell and tissue
extracts (SigmaeAldrich, St. Louis, U.S.A) 100 ul/1 ml, and
10 mM tris base (SigmaeAldrich, St. Louis, U.S.A), pH 7.4
and centrifuged at 1600 g at 4 C for 15 min. The superna-
tant was collected and total protein was measured with
Bio-Rad DC Protein Assay (Bio-RAD Laboratories, Hercules,
California, USA). Lung and right ventricular supernatant
was diluted 1:75 and 1:30, respectively. Plasma was diluted
1:10 and the fluids were used in an Apelin-12 kit (Phoenix
peptides, Burlingame, California, USA), following the
manufacturer’s instructions. The kit detects apelin-12, -13
and -36 with 100% cross reactivity, and has an inter-assay
variation of <14%. All samples were analysed in duplicate.
The coefficient of variation was calculated based on the
duplicate analyses. All samples from one type of tissue
were analysed in the same assay, to avoid inter-assay
variations. In each assay, a standard curve was included.
Also, the detection of apelin was controlled with a positive
control of diluted apelin peptide. Control experiments for
Table 1 Animal data.
N H Hþ S
RVSP (mmHg) 26.5 0.6 55.7 1.9* 44.7 2.8*y
BW (g) 327.2 8.3 281.9 2.7* 288.7 8.7*
LW (g) 1.33 0.04 1.65 0.04* 1.84 0.15*
LW/BW (%) 0.41 0.02 0.59 0.01* 0.64 0.05*
RV (g) 0.12 0.011 0.22 0.011* 0.19 0.009*
RV/LVþ S (%) 17.8 1.9 36.7 1.6* 31.4 2.0*
RV/BW (%) 0.037 0.004 0.078 0.004 0.067 0.003
LVþ S/BW 0.21 0.004 0.21 0.005 0.22 0.008
*p< 0.05 compared to normoxic rats.
yp< 0.05 compared to hypoxic rats.
Data are means SEM. n (N )Z 6, n (H )Z 7 and n (Hþ S )Z 6.
NZ normoxic rats, HZ hypoxic rats, Hþ SZ hypoxic sildenafil
treated rats, RVSPZ right ventricular systolic pressure,
BWZ body weight, LWZ lung weight, RVZ right ventricle and
LVþ SZ left ventricleþ septum.
Apelin as a marker for pulmonary hypertension? 1665non-specific colour reactions were performed. Absorbance
was read at 450 nm on an ELISA plate reader (ELx808
Ultraplate Reader, Biotek Instruments, Inc., UK).
Functional studies
In rats used for functional studies, pulmonary hypertension
was confirmed by the presence of right ventricular hyper-
trophy to avoid influence of anaesthetics.
3rd or 4th order branches of the pulmonary artery were
dissected and mounted in microvascular myographs for
isometric tension recordings. The organ bath containing PSS
was bubbled with 5% of CO2 in atmospheric air, heated to
37 C and the arteries were stretched to a level of tension
corresponding to a transmural pressure of 3.9 kPa.18
Contractile function was tested by depolarisation of the
cells with PSS containing 123.7 mM potassium (KPSS).
Arteries that responded with an increase in transmural
pressure of less than 2.7 kPa were discarded. Endothelial
cell function was evaluated by contracting the arteries with
the thromboxane analogue, U46619 (30 nM) (Sigmae
Aldrich, St. Louis, U.S.A) followed by acetylcholine (ACh)
(10 mM) (SigmaeAldrich, St. Louis, U.S.A).
To evaluate direct effects of apelin-13 (SigmaeAldrich,
St. Louis, U.S.A) on pulmonary arteries from normoxic and
hypoxic rats, the arteries were precontracted with U46619
(30 nM) and increasing concentrations of apelin-13 (1 nMe
3 mM) were added. Because of development of tachyphy-
laxis in arteries from normoxic rats, a single concentration
of apelin-13 (3 mM) was added in one line of experiments.
To investigate the effect of apelin-13 on contraction to
the pulmonary vasoconstrictors endothelin-1 (Sigmae
Aldrich, St. Louis, U.S.A) and the thromboxane analogue
U46619, half the vessels from each animal were randomized
to incubation with apelin (100 nM) for 20 min before per-
forming concentration-response curves for the compounds.
As a positive control of findings in systemic vascular tissue,
similar experiments were performed with angiotensin-II
(SigmaeAldrich, St. Louis, U.S.A).
Immunohistochemistry
Paraffin embedded sections of the lungs from normoxic and
hypoxic rats were obtained as previously described.18
Sections were pretreated with heat-induced epitopic
retrieval and incubated with anti-apelin receptor antibody
(Phoenix peptides, Burlingame, California, USA). The
sections were rinsed and the signal amplified with bio-
tinylated antibodies from the DAKO LSAB/HPR kit (DAKO).
Negative controls for each section were obtained by omis-
sion of the primary antibody. The strength of positive
immunoreactions in vascular endothelial cells, vascular
smooth muscle cells, and alveoli were scored by a blinded
observer.
Data analysis
Results were expressed as means SEM. Differences in
results between groups were analysed by Student’s t-test.
Correlation between apelin levels and manifestations of
pulmonary hypertension was analysed by linear regressiononly including animals where all measurements had been
obtained. The fold change in total apelin was calculated by
the following formula: (Csample/CmeanN) (OW/BWanimal)/
(OW/BWmean), where Csample is the concentration in each
sample, CmeanN is the mean concentration of the samples
from normoxic animals, OW/BWanimal is the organ to body
weight ratio in each animal and OW/BWmeanN is the organ to
body weight ratio in normoxic animals. Responses to apelin
were expressed as percentage of U46619-induced tension
and responses to vasoconstrictors as percent of tension
induced by KPSS after 3 min (mean SEM). Differences
between concentration-response curves were evaluated by
two-way analysis of variance (ANOVA). p-Values below 0.05
were considered statistical significant.
Results
Manifestations of pulmonary hypertension
Hypoxic rats had increased lung weight, increased right
ventricular pressures, and right ventricular hypertrophy.
Treatment with sildenafil only reduced the increase in right
ventricular pressure in the chronic hypoxic rats (Table 1).
Apelin assay
Based on the duplicate results from samples, the intra-
assay coefficient of variation was 10.0 1.16%. The func-
tional detection limit was 0.047 0.003 ng/ml with an
upper range limit of 0.243 0.03 ng/ml. The kit was able to
detect apelin peptide diluted in assay buffer.
Pulmonary apelin content
Total protein concentration pr mg of tissue was not signif-
icantly different in the three groups of animals (data not
shown).
Pulmonary apelin concentrations were 1.30 0.07 ng/mg
protein (nZ 6) in normoxic rats, and reduced to 1.10
0.06 ng/mg protein (nZ 7) in hypoxic rats (p< 0.05). In sil-
denafil treated rats, concentrations were 1.00 0.12 ng/mg
1666 C.U. Andersen et al.protein (nZ 6) which was not different from concentrations
in hypoxic rats (pZ 0.32) (Fig. 1a). The total pulmonary
apelin content corrected for lung and body weight was
calculated to investigate whether this would be reflected in
plasma. This was not changed by hypoxia (pZ 0.1, nZ 7) or
sildenafil treatment (Fig. 1b). There was no correlation
between pulmonary apelin concentrations or content and
right ventricular pressures.
Right ventricular apelin content
Right ventricular apelin concentrations were smaller than in
the lungs. Thus, in normoxic animals theconcentrationswere
0.15 0.04 ng/mg protein (nZ 6). In hypoxic animals
concentrations were 0.59 0.03 ng/mg protein (nZ 7)
(p< 0.05 versus normoxic rats). In sildenafil treated hypoxic
rats lung apelin concentrations were 0.65 0.05 ng/mg
protein (nZ 6), which was not different from apelin
concentrations in hypoxic, vehicle treated rats (pZ 0.33)
(Fig. 2a). When adjusted for right ventricular and body
weight, the total amount of apelin increased substantially in
chronic hypoxic rats (Fig. 2b). There was a strong correlation
of apelin concentrations and content to right ventricular
systolic pressure (Fig. 2ced).
Plasma apelin content
Plasma apelin concentrations were not changed by hypoxia
alone (pZ 0.12), but were increased by exposure to the
combination of hypoxia and treatment with sildenafil
(Fig. 3a).
Plasma apelin did not correlate to total pulmonary
apelin, and only weakly to right ventricular apelin content
(Fig. 3b). There was no correlation between plasma apelin
levels and right ventricular systolic pressure.
Functional studies
Arteries had a diameter of 494 26 mm. Acetylcholine
(10 mM) induced relaxations of 69 3% (nZ 12) and 69 6%= N = H
N H H+S
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Figure 1 Pulmonary apelin content. (a) Apelin concentration pr m
expressed as fold change of content in normoxic animals (normalis
and n (Hþ S )Z 6. *p< 0.05 compared to normoxic rats. NZ no
treated rats.(nZ 7) in arteries from normoxic and hypoxic animals,
respectively.
In pulmonary arteries from normoxic rats, cumulatively
added concentrations of apelin-13 did not elicit any response.
A single concentration of apelin-13 (3 mM) induced transient
relaxations of 17 4% (p< 0.05, nZ 5) (Fig. 4a,b). In
pulmonary arteries fromhypoxic rats, a similar relaxationwas
inducedwhenaconcentrationofapelin-13 (3 mM)was reached
when performing concentration-response curves (Fig. 4c,d).
In arteries from normoxic rats, incubation with apelin-13
(100 nM) had no effect on U46619 contraction (Fig. 5a), but
attenuated the response to endothelin-1 and angiotensin-II
(Fig. 5b,c). In the arteries from hypoxic rats, there was no
effect of incubation with apelin-13 on vasoconstriction
induced by either U46619 (Fig. 5d), endothelin-1 (Fig. 5e),
or angiotensin-II (Fig. 5f).
Apelin receptor distribution
Immunoreaction for apelin receptors was present in the
vascular endothelium and to a lesser extent in smooth
muscle cells of pulmonary arteries with internal diameters
of 400e600 mm corresponding in size to those used for
functional experiments (Fig. 6a,b). Also, immunoreaction
for apelin receptors was present in the respiratory epithe-
lium. No immunoreaction was detected in control sections
when the primary antibody was omitted (Fig. 6c). When
scoring the strength of the expression, no difference in the
distribution or density of the immunoreaction for apelin
receptors in the endothelium (1.6 0.4 versus 2.1 0.4,
pZ 0.3), smooth muscle cells (0.54 0.15 versus
0.54 0.12, pZ 0.9), and alveoli was detected between
pulmonary tissue from normoxic and hypoxic rats.
Discussion
This study is the first to address pulmonary apelin protein
levels and the effect of apelin in pulmonary arteries in a rat
model of chronic hypoxic pulmonary hypertension. The
main findings are that while apelin protein concentration in= H+S
N H H+S
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Figure 2 Right ventricular apelin content. (a) Apelin concentration pr mg tissue. (b) Apelin content adjusted for lung and body
weight expressed as fold change of content in normoxic animals (normalised to 1). (c) And (d) correlation of concentrations and
content to right ventricular systolic pressure. Data are shown as mean SEM. n (N )Z 6, n (H )Z 7 and n (Hþ S )Z 6. NZ nor-
moxic rats, HZ hypoxic rats, Hþ SZ hypoxic sildenafil treated rats and RVSPZ right ventricular systolic pressure.
Apelin as a marker for pulmonary hypertension? 1667lung tissue decreased, the total pulmonary apelin content
remained stable because of a corresponding increase in
pulmonary tissue mass. In the right ventricle, a substantial
increase in apelin content that correlated strongly to right
ventricular pressure was found, suggesting that apelin levels
in the heart are more specifically related to hemodynamic
changes. In pulmonary arteries from normoxic rats, apelin
counteracted vasoconstriction in response to endothelin-1.
In arteries from hypoxic rats, this effect was abolished sug-
gesting that the effect of the peptide is altered in chronic
hypoxic rats. However, no difference in the expression of
apelin receptors was detected. Therefore, alterations in the
intracellular signalling pathways activated by apelin may
account for the altered response in pulmonary arteries from
chronic hypoxic rats.
Pulmonary apelin
Previous studies have suggested that hypoxia alters apelin
in the lungs. Thus, in mice an increase in total pulmonary
apelin mRNA was reported to take place after one week of
hypoxia,19 and in another study in mice, approximately
a doubling of apelin mRNA and an increase of apelin protein
of about 25% was found after 5 h of hypoxia.20 However,
some endothelial proteins are regulated in opposite direc-
tions by acute and chronic hypoxia,21 and the species may
influence the response of the apelin pathway to hypoxia.Thus, in the present study chronic hypoxia (two weeks)
caused an increase of lung weight with a decreased amount
of apelin pr mg of tissue. Two weeks of hypoxia has been
shown to cause inflammation, collagen deposition in alve-
olar septae and vessel walls, decreased staining for endo-
thelial cells,22 and increased muscularization of small
pulmonary arteries,18 resulting in increased lung weight.
The unaltered total apelin amount and lowered apelin
protein concentrations pr mg of tissue could, therefore,
reflect a decrease of the relative mass of apelin containing
endothelial cells.
Apelin in the heart
In the heart, heart failure and hypoxia have been shown to
regulate apelin levels. In a murine study, short-term hypoxia
upregulated left ventricular apelin mRNA,19 and in models of
ischemic heart failure total heart apelin protein was upregu-
lated 6 weeks after induction of myocardial infarction.23
Because of apelins well-demonstrated positive inotropic
effect,12,23 the early upregulation is thought to be a compen-
satory mechanism.23 However, in rats with decompensated
heart failure, levels were downregulated,24 suggesting that
apelin levels in the heart are regulated differently in short-
and long-term heart failure. In agreement with the previous
studies,19,23 the rats in the present study had right ventricular
hypertrophy, and both concentration and total content of
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Figure 3 Plasma apelin content. (a) Plasma apelin concentrations. (b) Correlations of plasma apelin and adjusted right
ventricular apelin levels. n (N )Z 6, n (H )Z 7 and n (Hþ S )Z 6. NZ normoxic rats, HZ hypoxic rats and Hþ SZ hypoxic sil-
denafil treated rats. *p< 0.05 compared to normoxic animals.
1668 C.U. Andersen et al.apelin was markedly increased in the right ventricle. The
correlation to the right ventricular pressure suggests that the
changes in apelin levels are induced by pressure load of the
right ventricle.
Plasma apelin
Plasma apelin concentrations have been shown to be
decreased in patients with pulmonary hypertension, severe
chronic obstructive lung disease (COPD), and left heart
failure.10,25,26 However, it is unclear whether plasma apelin
reflects apelin levels in the organs involved in the diseases.
As apelin is highly expressed in pulmonary tissue,11 it was
speculated that pulmonary apelin could be a major source
of plasmatic apelin.10 However, apelin is also present in
adipose tissue and has been found in systemic vessels,
where the mRNA expression was also upregulated byFigure 4 Direct effect of apelin. (a) Effect of cumulatively adde
moxic rats. (b) Example of original trace showing the effect of on
from normoxic animal without prior exposure to the peptide. (c)
pulmonary arteries from hypoxic rats. (d) Example of original trac
artery from hypoxic animal. The effect of apelin is expressed as per
ANOVA compared to normoxic vessels. nZ 3e7. NAZ apelin treat
pulmonary arteries from hypoxic animals, HCZ vehicle treated
AZ apelin.hypoxia or heart failure in animal models or cell
cultures.19,27 Since COPD, pulmonary hypertension and
heart failure all result in some degree of tissue hypoxia,
apelin from these sources could also contribute to disease-
related alterations in plasmatic apelin levels. Indeed, in the
present study, plasma apelin did not reflect pulmonary
concentrations or content and correlated only weakly to
apelin levels in the right ventricle. These findings suggest
that apelin from other sources may play a role for plasma
apelin levels.
Interestingly, we found that while plasma concentra-
tions were not changed by exposure to hypoxia per se, the
combination of hypoxia and sildenafil increased the
concentration significantly. Previous studies have shown
that NO increases apelin receptor mRNA in rat brain,28 but
so far it is unknown whether the NOecGMP pathway may
also influence apelin formation.d concentrations of apelin-13 in pulmonary arteries from nor-
e single concentrations of apelin added to a pulmonary artery
Effect of cumulatively added concentrations of apelin-13 in
e from concentration-response curve for apelin in pulmonary
centage of contraction to U46619 (30 nM). *p< 0.05 by two-way
ed pulmonary arteries normoxic animals, HAZ apelin treated
pulmonary arteries from hypoxic animals, UZ U46619 and
NC HAHCNA
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Figure 5 Effects of incubation with apelin and hypoxia on responses to vasoconstrictors in pulmonary arteries from normoxic and
hypoxic rats. (aec) Effect of apelin-13 on contraction to (a) U46619, (b) endothelin-1 and (c) angiotensin-II in arteries from nor-
moxic rats. (def) Effect of apelin-13 on contraction to (d) U46619, (e) endothelin-1 and (f) angiotensin-II in arteries from hypoxic
rats. Data are shown as mean SEM of tension in percent of the maximal contraction to KPSS 124 mM. *p< 0.05 by two-way ANOVA
compared to normoxic control vessels. KPSSZ physiological salt solution with potassium, 124 mM. NCZ pulmonary arteries from
normoxic animals, vehicle treated; NAZ pulmonary arteries from normoxic animals, apelin treated; HCZ pulmonary arteries from
hypoxic animals, vehicle treated and HAZ pulmonary arteries from hypoxic animals, apelin treated. NZ 5e10.
Apelin as a marker for pulmonary hypertension? 1669Functional effects of apelin in pulmonary arteries
and distribution of receptors
Apelin receptors have been proven to be localised in
vascular endothelial cells, vascular smooth muscle cells,
and cardiomyocytes in humans as well as in bronchial
epithelial cells in rats.29 It is believed that apelin receptor
activation in smooth muscle cells and cardiomyocytes
results in contraction, whereas in endothelial cells it causes
NO release leading to vasorelaxation.30 Apelin receptorprotein quantified by western blotting has been shown to
be upregulated in pulmonary tissue in mice after one week
of hypoxia.19
Whether the relaxation in response to 3 mM of apelin-13
is of physiological significance is uncertain, but due to the
close proximity of the peptide and receptors, the local
concentration around the receptors could be significantly
higher than measured in plasma. However, compared to
other substances, such as sildenafil,18 apelin does not seem
to be a potent pulmonary vasodilator.
Figure 6 Receptor distribution and density. (aeb) Lung
section with pulmonary artery stained with anti-apelin
receptor antibody from normoxic (a) and hypoxic rat (b).
(c) Negative control.
1670 C.U. Andersen et al.The fact that 100 nM of apelin counteracted contraction
to endothelin-1 and angiotensin-II, but not to U46619 in
arteries from normoxic animals suggests that apelin does
not have a general inhibitory effect on vasoconstriction.
The absence of the inhibitory effect of apelin on endo-
thelin-1 and angiotensin-II contraction in pulmonary
arteries from chronic hypoxic rats was probably not caused
by a generally impaired endothelial NO production, sincerelaxation induced by acetylcholine was similar in arteries
from normoxic and hypoxic animals. With respect to apelin
receptors, localisation in the endothelium, smooth muscle
cells and epithelium concurs with previous findings.29
However, immunoreaction for the apelin receptor did not
suggest differences in receptor density or localisation.
These findings suggest that the changed apelin response
rather can be ascribed to alterations in the signalling
pathways downstream of the apelin receptor.
Conclusions
Pulmonary apelin content was unchanged by hypoxia and
did not correlate to plasma apelin levels, which does not
speak in favour of apelin as a lung-derived plasma marker
of pulmonary hypertension. Furthermore, apelin only
modulated vasoconstrictor tone in arteries from normoxic
rats, an effect which was lost in hypoxia. On the other
hand, apelin levels in the right ventricle were closely
related to right ventricular pressure. This is indeed an
attractive quality for a biomarker of pulmonary hyperten-
sion, but right ventricular levels were only weakly reflected
in plasma, suggesting that additional tissue sources
contribute to plasma apelin concentrations.
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